Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

DexCom

Insulet

These three medtech companies are at the forefront of diabetes care.

3 Top Diabetes Stocks to Watch in July

EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (NASDAQ:TNDM) Brian B Hansen (insider trades) sold 13,031 shares of TNDM on 07/11/2019 at an average price of $70.04 a share.

Tandem Diabetes Care Inc (TNDM) EVP & CHIEF COMMERCIAL OFFICER Brian B Hansen Sold $912,691.

Coeur Mining

Spark Therapeutics

Find out what made these stocks miss out on a rally.

Why Coeur Mining, Spark Therapeutics, and Tandem Diabetes Care Slumped Today

Medtronic

Tandem Diabetes stock skidded Monday as investors questioned whether the medical devices maker could catch up to industry leader Medtronic in diabetes treatment using a pump and monitor.
The post How The David Of Diabetes Devices Is Taking On Goliath — And Why Shares Dipped appeared first on Investor's Business Daily.

How The David Of Diabetes Devices Is Taking On Goliath — And Why Shares Dipped

The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.

Tandem Releases Positive Results Of t:slim X2 Pump Studies

The business reported first-quarter 2019 earnings -- and more positive news since.

Here's Why Tandem Diabetes Care Rose 11.6% in May

VMware

Workday

Do you panic during periods of volatility, or do you see opportunity?

Stock Exchange: Lemons, Lemonade Or Rip Van Winkle

Tandem Diabetes continues to operate in the sweet spot of medical technology-gaining share in the growing market of insulin pumps.

Tandem Diabetes: Strong Business Trends Should Continue Due To Market Growth And Share Gains

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock?

Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?

Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.

Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q1 2019 Results - Earnings Call Transcript

Tandem Diabetes (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Tandem Diabetes (TNDM) Report Negative Earnings Next Week? What You Should Know

The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.

What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?

Abbott Labs

Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.

A Diabetes Treatment Revolution Could Bolster These Medtech Firms

Worries about what might happen with the U.S. healthcare system took a toll on the insulin-pump maker's share price.

Why Tandem Diabetes Care Stock Sank Today

Find out why our team of healthcare experts is laser-focused on these diabetes stocks right now.

3 Top Diabetes Stocks to Watch in April

ABIOMED

Align Technology

Intuitive Surgical

Medical device stocks were hot in 2018. Here's which ones could sizzle in 2019.

5 Top Medical Device Stocks for 2019

Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Tandem Diabetes (TNDM) Up 1.8% Since Last Earnings Report?

Tandem Diabetes' insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.

Tandem Diabetes Signs as an Insulin Pump Vendor in Canada

We can attribute Tandem Diabetes Care stock's stellar performance last month largely to two company-specific catalysts.

News for Tandem Diabetes Care Stock (TNDM)